Abstract:Key PointsThe liver provides a useful generic model of inflammation and repair, showing the complex interplay between the epithelial, inflammatory, myofibroblast and extracellular matrix (ECM) components of the mammalian wound-healing response. In almost all situations, fibrosis is preceded by inflammation and elements of both the innate and adaptive immune systems are crucial in regulating the fibrotic process.Following liver injury, pro-inflammatory mediators that are generated by cellular damage and stimulated immune cells, as well as growth factors and cytokines (including platelet-derived growth factor, connective tissue growth factor, transforming growth factor-β and interleukin-13), activate mesenchymal precursor cells in tissues and induce their transdifferentiation into myofibroblasts. Myofibroblasts are master regulators of the fibrotic response as a result of their acquisition of scar-producing, proliferative, migratory, contractile, immunomodulatory and phagocytic properties.Recent studies have used bone marrow transplantation techniques in reporter mice to show that, regardless of the aetiology or the duration of the injury, liver myofibroblasts are almost exclusively derived from the activation of resident mesenchymal cells. Perpetuation of myofibroblast fibrogenic activity is mediated through several positive feedback loops, involving the autocrine and paracrine effects of cytokines and growth factors, and cell–cell and cell–matrix interactions. Myofibroblasts themselves function as innate immune cells.The balance of T helper 1 (TH1) cell-mediated and TH2 cell-mediated adaptive immune responses, the influence of unconventional T cell subsets and the equilibrium between different pro-inflammatory (that is, pro-fibrotic) and pro-resolution macrophage populations determine whether the outcome of tissue injury is homeostatic and self-limited or whether it results in pathogenic scarring.Liver fibrosis in rodents and humans is a dynamic, bidirectional process that has an inherent capacity for recovery and remodelling. The loss of myofibroblasts from the hepatic scar and a crucial switch in macrophage phenotype to a pro-resolution cell type are important events in the regression of liver fibrosis that facilitate remodelling of the ECM.A considerable number of tractable therapeutic targets have been identified in liver fibrosis, but clinical trials of anti-fibrotic therapies have so far been unsuccessful. Identification of the core pathways in fibrosis is likely to yield greater success in clinical translation.

Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy

Liver Fibrosis: From Pathogenesis to Novel Therapies

Liver fibrosis and repair: immune regulation of wound healing in a solid organ

Novel Immune Subsets and Related Cytokines: Emerging Players in the Progression of Liver Fibrosis

Hepatic fibrosis: From bench to bedside

Regulation of Progression and Resolution of Liver Fibrosis by Immune Cells

Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis

Modification of Chemokine Pathways and Immune Cell Infiltration as a Novel Therapeutic Approach in Liver Inflammation and Fibrosis

Liver Fibrosis Resolution: from Molecular Mechanisms to Therapeutic Opportunities

Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis

An update on the recent advances in antifibrotic therapy

Emerging Therapies for Liver Fibrosis

Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy

Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives

Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis

Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression

Molecular and cellular mechanisms of liver fibrosis and its regression

Clinical Advancements in the Targeted Therapies against Liver Fibrosis